Institution
Chonbuk National University
Education•Jeonju, South Korea•
About: Chonbuk National University is a education organization based out in Jeonju, South Korea. It is known for research contribution in the topics: Apoptosis & Graphene. The organization has 14820 authors who have published 28884 publications receiving 554131 citations.
Topics: Apoptosis, Graphene, Nanofiber, Population, Electrospinning
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, a search for the production of Higgs boson pairs in proton-proton collisions at a centre-of-mass energy of 13 TeV is presented, using a data sample corresponding to an integrated luminosity of 35.9fb^(−1) collected with the CMS detector at the LHC.
123 citations
••
TL;DR: It is concluded that the clinical characteristics of breast cancer have changed over the past 10 years in Korea, and surgical management has changed accordingly.
Abstract: The Korean Breast Cancer Society has constructed a nationwide breast cancer database through utilization of an online registration program. We have reported the basic facts about breast cancer in Korea in 2012, and analyzed the changing patterns in the clinical characteristics and management of breast cancer in Korea over the last 10 years. Data on patients newly diagnosed with breast cancer were collected for the year 2012 from 97 hospitals and clinics nationwide using a questionnaire survey, and from the online registry database. A total of 17,792 patients were newly diagnosed with breast cancer in 2012. The crude incidence rate of female breast cancer, including invasive cancer and in situ cancer, was 70.7 cases per 100,000 women. The median age at diagnosis was 51 years, and the proportion of postmenopausal women was higher than that of premenopausal women among those diagnosed with breast cancer. The proportion of cases of early breast cancer increased continuously, and breast-conserving surgery was performed in more cases than total mastectomy in that same year. The total number of breast reconstruction surgeries increased approximately 3-fold over last 10 years. The 5-year overall survival rate for all stages of breast cancer patients was extremely high. The clinical characteristics of breast cancer have changed in ways that resulted in high overall survival over the past 10 years in Korea, and the surgical management of the disease has changed accordingly. Analysis of nationwide registry data will contribute to a better understanding of the characteristics of breast cancer in Korea.
123 citations
••
TL;DR: Ex vivo analysis of β-islets showed that EGCG downregulates the MLD-STZ-induced expression of inducible NOS (iNOS), and morphological examination showed thatEGCG treatment ameliorated the decrease of islet mass induced by MLD -STZ, suggesting that E GCG could prevent the onset of MLD, STZ- induced diabetes by protecting pancreatic islets.
Abstract: Cytokines produced by immune cells infiltrating pancreatic islets have been incriminated as important mediators of β-cell destruction in insulin-dependent diabetes mellitus. In non insulin-dependent diabetes, cytokines are also associated with impaired β-cell function in high glucose condition. By the screening of various natural products blocking β-cell destruction, we have recently found that epigallocatechin gallate (EGCG) can prevent thein vitro destruction of RINm5F cell, an insulinoma cell line, that is induced by cytokines. In that study we suggested that EGCG could prevent cytokine-induced β-cell destruction by down-regulation of nitric oxide synthase (NOS) through inhibition of NF-κB activation. Here, to verify thein vivo antidiabetogenic effect of EGCG, we examined the possibility that EGCG could also prevent the experimental autoimmune diabetes induced by the treatment of multiple low doses of streptozotocin (MLD-STZ), which is recognized as an inducer of type I autoimmune diabetes. Administration of EGCG (100 mg/day/kg for 10 days) during the MLD-STZ induction of diabetes reduced the increase of blood glucose levels caused by MLD-STZ.Ex vivo analysis of β-islets showed that EGCG downregulates the MLD-STZ-induced expression of inducible NOS (iNOS). In addition, morphological examination showed that EGCG treatment ameliorated the decrease of islet mass induced by MLD-STZ. In combination these results suggest that EGCG could prevent the onset of MLD-STZ-induced diabetes by protecting pancreatic islets. Our results therefore revealed the possible therapeutic value of EGCG for the prevention of diabetes mellitus progression.
123 citations
••
TL;DR: In this article, a simple and cost-effective method of fabricating hybrid transparent conductive electrodes (TCEs) based on embedded silver nanowires (Ag NWs)/PEDOT: PSS was developed with the addition of low-temperature synthesis of Ni(OH)2 and polyethylenimine ethoxylated (PEIE) composites as a novel interlayer.
123 citations
••
Catholic University of Korea1, Ajou University2, Chonnam National University3, Dong-a University4, Hallym University5, Sungkyunkwan University6, University of Ulsan7, Keimyung University8, Chonbuk National University9, Ewha Womans University10, Inje University11, Gachon University12, Chungbuk National University13
TL;DR: Positivity (defined as ≥ 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before Imatinib discontinuation were associated with a higher probability of sustained major molecular response and minimal residual leukemia measured by digital polymerases chain reaction had a trend for a higher molecular relapse.
Abstract: The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as ≥ 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse. (Trial registered at ClinicalTrials.gov: NCT01564836).
123 citations
Authors
Showing all 14943 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hyun-Chul Kim | 176 | 4076 | 183227 |
Andrew Ivanov | 142 | 1812 | 97390 |
Dong-Chul Son | 138 | 1370 | 98686 |
C. Haber | 135 | 1507 | 98014 |
Tae Jeong Kim | 132 | 1420 | 93959 |
Alessandro Cerri | 129 | 1244 | 103225 |
Paul M. Vanhoutte | 127 | 868 | 62177 |
Jason Nielsen | 125 | 893 | 72688 |
Chi Lin | 125 | 1313 | 102710 |
Paul Lujan | 123 | 1255 | 76799 |
Young Hee Lee | 122 | 1168 | 61107 |
Min Suk Kim | 119 | 975 | 66214 |
Alexandre Sakharov | 119 | 582 | 56771 |
Yang-Kook Sun | 117 | 781 | 58912 |
Rui L. Reis | 115 | 1608 | 63223 |